In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Compugen (CGEN – Research Report), with a price target of $4.00. The company’s shares closed last Friday ...

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Clearly, recent earnings estimate revisions suggest that good things are ahead for Compugen, and that a beat ...

Compugen has a 12 month low of $1.35 and a ... 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Several institutional investors have recently made ...

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on ...

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is advancing a portfolio of innovative immunotherapy ...

Compugen is driving the discovery and development of cancer immunotherapy drugs using its proprietary computational solutions, advanced new omics technologies and integration of computational ...

But note: Compugen may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

HOLON, Israel, Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...